Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might ...

Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

Amgen Inc.'s stock took a hit Monday after the biotechnology giant lost a bull, amid concerns that prices already reflect investor optimism over the obesity drug candidate, leaving more downside risks ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...